Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

Trial Details

NCT ID
NCT04918186
Phase
PHASE2
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Durvalumab
  • BA3011
  • BA3021
  • ENB003
  • Toripalimab
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Kelowna, British Columbia, Canada|49.88307,-119.48568
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • This study will enroll women with platinum resistant high grade serous ovarian cancer.
  • This study is open to minorities as appropriate but is not designed to measure differences in intervention effects.
  • All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment…
  • Additional Criteria To Be Met Prior To Sub-study Enrollment All patients must fulfill all of the following criteria to be eligible for enrollment t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →